Brief: Aligos Therapeutics Presents Clinical, Nonclinical Data Demonstrating Alg-055009 Has Favorable Risk-Benefit Profile
13/11/2023 14:27
Nov 13 (Reuters) - Aligos Therapeutics Inc ALGS.O :
* ALIGOS THERAPEUTICS - PRESENTS CLINICAL, NONCLINICAL DATA
AT
AASLD LIVER MEETING 2023 DEMONSTRATING ALG-055009 HAS FAVORABLE
RISK-BENEFIT PROFILE
Source text for Eikon: ID:nGNX1jlG4Q
Further company coverage: ALGS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aligos Therapeutics
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
U.S. RESEARCH ROUNDUP-Ciena Corp, Docusign, Snowflake
Brief: Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China
Aligos Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aligos Therapeutics Q2 net loss narrows on licensing revenue